<DOC>
	<DOCNO>NCT00734890</DOCNO>
	<brief_summary>RATIONALE : Vandetanib may stop growth cancer cell block enzymes need cell growth . Monoclonal antibody , bevacizumab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Bevacizumab vandetanib may also stop growth cancer cell block blood flow cancer . Giving vandetanib together bevacizumab may kill cancer cell . PURPOSE : This phase I trial study side effect best dose vandetanib bevacizumab treat patient advance solid tumor lymphoma .</brief_summary>
	<brief_title>Vandetanib Bevacizumab Treating Patients With Advanced Solid Tumors Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose , safety , toxicity vandetanib bevacizumab patient advance solid tumor lymphoma . Secondary - Characterize pharmacokinetic profile regimen patient . - Measure change VEGF angiogenic cytokine plasma sample patient . - Determine biochemical change EGF signal transduction pathway tumor biopsy sample patient . - Determine anti-angiogenic effect regimen tumor biopsy sample patient . - Evaluate application dynamic contrast-enhanced MRI determine early change tumor vascular permeability treatment . - Evaluate effect regimen circulate endothelial progenitor mature circulate endothelial cell patient . OUTLINE : Patients receive oral vandetanib daily day 1-21 bevacizumab IV 30-90 minute day 1 . Courses repeat every 3 week absence disease progression unacceptable toxicity . Patients undergo blood sample collection periodically correlative laboratory study , include pharmacokinetic , biomarker ( VEGF angiogenic cytokine ) , circulate endothelial cell analysis . Patients may also undergo optional tumor biopsy additional correlative laboratory study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced malignancy , include follow : Solid tumor refractory standard therapy standard therapy exist No lung carcinoma squamous cell small cell histology ( mixed tumor categorize predominant cell type ) Histological confirmation base sputum cytology alone acceptable Lymphoma ( Hodgkin nonHodgkin lymphoma ) progress standard therapy AND stem cell transplantation indicate refuse No known CNS disease , except treat brain metastasis meeting follow criterion : No ongoing requirement steroid No evidence progression hemorrhage clinical examination brain imaging ( MRI CT scan ) ≥ 3 month treatment Stable dose anticonvulsant allow Prior treatment brain metastasis may include wholebrain radiotherapy , radiosurgery ( gamma knife , linear accelerator , equivalent ) , combination therapy deem appropriate treating physician Neurosurgical resection brain biopsy treatment CNS metastases allow provided treatment complete 3 month ago PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 02 OR Karnofsky PS 60100 % Life expectancy &gt; 3 month Absolute neutrophil count ≥ 1,500/μL Platelet count ≥ 100,000/μL Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN Creatinine &lt; 1.5 time ULN OR creatinine clearance ≥ 60 mL/min Urine protein : creatinine ratio ≤ 0.5 OR urine protein &lt; 1,000 mg 24hour urine collection Activated partial thromboplastin time ≤ 1.5 time ULN Prothrombin time OR INR &lt; 1.5 time ULN Potassium 4 mmol/L ULN ( supplementation allow ) Magnesium normal ( supplementation allow ) Serum calcium ( adjust albumin ) ionize calcium normal ( supplementation allow ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ≥ 6 month completion study therapy HIVpositivity allow provide follow criterion meet : Patient require antiHIV therapy CD4 count &gt; 350/mm^3 HIV viral load &lt; 25,000 copies/mm^3 No history opportunistic infection No evidence severe uncontrolled systemic disease concurrent condition could compromise participation study , include follow : Active uncontrolled infection Immune deficiencies HIV infection require antiHIV therapy Hepatitis B Hepatitis C Uncontrolled diabetes Uncontrolled hypertension Symptomatic congestive heart failure Unstable angina pectoris Myocardial infarction within past 6 month Uncontrolled cardiac arrhythmia Stroke/cerebrovascular accident within past 6 month Psychiatric illness/social situation , investigator 's opinion , would make undesirable patient participate study would jeopardize study compliance No New York Heart Association class III IV heart disease within past 6 month No history arrhythmia ( i.e. , multifocal premature ventricular contraction , bigeminy , trigeminy , ventricular tachycardia , uncontrolled atrial fibrillation ) symptomatic require treatment Atrial fibrillation allow provide controlled medication No asymptomatic sustain ventricular tachycardia No cardiac disease , investigator 's opinion , would increase risk ventricular arrhythmia QTc &lt; 480 msec ( measurable Bazett correction ) screen ECG No history QTc prolongation result medication require discontinuation No congenital long QT syndrome No firstdegree relative unexplained sudden death 40 year age No leave bundle branch block No hypertension control medical therapy , define systolic blood pressure &gt; 150 mm Hg diastolic blood pressure &gt; 90 mm Hg despite optimal medical management No clinically significant cardiac event No thromboembolic disease within past 6 month No significant vascular disease ( e.g. , aortic aneurysm aortic dissection ) clinically significant peripheral vascular disease No serious nonhealing wound ( include wound heal secondary intention ) No acute nonhealing ulcer No bone fracture within past 3 month No abdominal fistula , gastointestinal perforation , intraabdominal abscess within past 28 day No currently active diarrhea may affect ability patient absorb tolerate vandetanib No hemoptysis ( bright red blood ≥ ½ teaspoon per episode ) within past 3 month No known hypersensitivity Chinese hamster ovary cell product recombinant human antibody PRIOR CONCURRENT THERAPY : See Disease Characteristics Prior antiVEGF therapy allow More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin C ) radiotherapy recover More 4 week since prior major surgery recover At least 2 week since prior investigational drug give phase 0 clinical trial More 10 day since prior concurrent aspirin ( &gt; 325 mg/day ) chronic use NSAIDs No concurrent regular , therapeutic anticoagulation No concurrent medication may cause QTc prolongation , induce Torsades de Pointes , induce CYP3A4 function , include follow : Rifampin Rifabutin Phenytoin Carbamazepine Phenobarbital Hypericum perforatum ( St. John 's wort ) No concurrent antineoplastic therapy , except gonadotropinreleasing hormone therapy prostate cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>AIDS-related diffuse large cell lymphoma</keyword>
	<keyword>AIDS-related diffuse mixed cell lymphoma</keyword>
	<keyword>AIDS-related diffuse small cleave cell lymphoma</keyword>
	<keyword>AIDS-related immunoblastic large cell lymphoma</keyword>
	<keyword>AIDS-related lymphoblastic lymphoma</keyword>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>AIDS-related small noncleaved cell lymphoma</keyword>
	<keyword>HIV-associated Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>Waldenström macroglobulinemia</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>post-transplant lymphoproliferative disorder</keyword>
	<keyword>cutaneous B-cell non-Hodgkin lymphoma</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>adenosquamous cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
</DOC>